Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218887 · ClinicalTrials.gov registry record · Phase 1
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
A Phase 1 study of BAG3 Mutation Associated Dilated Cardiomyopathy, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 7
- Study locations
NCT07218887: Recruiting Phase 1 study of BAG3 Mutation Associated Dilated Cardiomyopathy, sponsored by Alexion Pharmaceuticals.
NCT07218887 is a Phase 1 study of BAG3 Mutation Associated Dilated Cardiomyopathy that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07218887, a Phase 1 study of BAG3 Mutation Associated Dilated Cardiomyopathy, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 7
- Study locations
Study Summary
This Phase 1/2 study is an open-label, dose finding and dose expansion study investigating the safety, tolerability, and efficacy of a single IV infusion of ALXN2350 in adult participants with BAG3 associated DCM.
Conditions Studied
Interventions
- DRUG ALXN2350
Study Locations (7)
Other
- Research Site - Barcelona
- Research Site - Majadahonda
Alabama
- Research Site - Birmingham
Massachusetts
- Research Site - Boston
Ohio
- Research Site - Cincinnati
Oregon
- Research Site - Portland
Texas
- Research Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2025-10-24 |
| Est. Completion | 2032-01-27 |
| Phase | Phase 1 |
What NCT07218887 shows while recruiting
NCT07218887 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 1 condition, with BAG3 Mutation Associated Dilated Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which ALXN2350 is the first listed.
NCT07218887 lists 7 locations in 6 states (Other, Alabama, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT07218887 about?
NCT07218887 is a clinical study titled "ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy". This Phase 1/2 study is an open-label, dose finding and dose expansion study investigating the safety, tolerability, and efficacy of a single IV infusion of ALXN2350 in adult participants with BAG3 associated DCM.
What is the current status of trial NCT07218887?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2025-10-24. Estimated completion is 2032-01-27.
What conditions does trial NCT07218887 study?
This clinical trial studies the following conditions: BAG3 Mutation Associated Dilated Cardiomyopathy.
What interventions are being tested in trial NCT07218887?
The interventions under investigation include: ALXN2350 (DRUG).
Who is sponsoring clinical trial NCT07218887?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07218887 being conducted?
This trial has 7 study locations across Alabama, Massachusetts, Ohio, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07218887's enrollment target sits among peer trials
6 1975th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI